The Cardiovascular Implications of Gender-Affirming Estrogen Therapy Use in Transgender Women

Simple item page
dc.contributor.advisorAhmed, Sofia Bano
dc.contributor.authorRytz, Chantal Louise
dc.contributor.committeememberSaad, Nathalie
dc.contributor.committeememberDumanski, Sandra Marie
dc.contributor.committeememberRonksely, Paul Everett
dc.contributor.committeememberRaj, Satish R.
dc.contributor.committeememberSomayaji, Ranjani
dc.date2024-05
dc.date.accessioned2024-04-30T17:41:54Z
dc.date.available2024-04-30T17:41:54Z
dc.date.issued2024-04-24
dc.description.abstractCardiovascular disease is a leading cause of death globally, with transgender and gender diverse (TGD) individuals, and particularly transgender women (sex assigned male at birth who identify as women) facing significant rates of cardiovascular-related morbidity and mortality. While uncertainties exist regarding the potential contribution of gender-affirming estrogen therapy in the increased cardiovascular risk noted in this population, there remains a critical evidence gap in understanding how factors such as serum estradiol levels, sex assigned at birth, and gender identity impact cardiovascular risk. Therefore it was the objective of this thesis to determine the cardiovascular implications of gender-affirming hormone therapy in transgender women, which was explored from various angles through conducting three independent studies. Our first study provides an understanding of the association between serum estradiol and cardiovascular-related mortality, adverse cardiovascular events and cardiovascular related risk factors using a systematic review and meta-analysis approach. We determined that the rate of serum estradiol change across the use of gender-affirming estrogen therapy may influence cardiovascular risk factors, which may have implications for clinical cardiovascular outcomes. Using a cross-sectional approach, our second study evaluated the impact of gender identity and sex assigned at birth on measures of vascular hemodynamics and arterial stiffness in transgender women as compared to cisgender women and men. Our findings underscore the importance of considering gender identity in addition sex assigned at birth when evaluating measures of cardiovascular health and risk. Our final study addressed the major methodological limitation with retrospective studies within the TGD population by generating and validating numerous case-definitions to identify both transgender women and men in routinely-collected healthcare data in Alberta, Canada. By linking numerous administrative data sources and testing against a reference standard of self-identified gender identity, a combination of using sex assigned in provincial registry and exogenous hormone dispensations or TGD-related billing codes were the most sensitive at identifying TGD individuals, and were employed to approximate both prevalence and incidence per 100,000 person-years, providing a first-ever assessment of the TGD population within Alberta. Despite recent advances and calls for the incorporation of both sex and gender into health research and clinical care, gaps in the understanding of cardiovascular health in transgender women remain. Our findings highlight numerous factors that may be implicated in cardiovascular health and risk in the transgender women population. This thesis may inform areas for further interventions aimed at improving cardiovascular health, mitigating cardiovascular disease risk, and exploring clinical cardiovascular outcomes in transgender women.
dc.identifier.citationRytz, C. L. (2024). The cardiovascular implications of gender-affirming estrogen therapy use in transgender women (Doctoral thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.
dc.identifier.urihttps://hdl.handle.net/1880/118528
dc.identifier.urihttps://doi.org/10.11575/PRISM/43370
dc.language.isoen
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgary
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjecttransgender health
dc.subjecttransgender women
dc.subjectgender-affirming estrogen therapy
dc.subjectphysiology
dc.subjectepidemiology
dc.subject.classificationMedicine and Surgery
dc.titleThe Cardiovascular Implications of Gender-Affirming Estrogen Therapy Use in Transgender Women
dc.typedoctoral thesis
thesis.degree.disciplineMedicine – Medical Sciences
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameDoctor of Philosophy (PhD)
ucalgary.thesis.accesssetbystudentI do not require a thesis withhold – my thesis will have open access and can be viewed and downloaded publicly as soon as possible.
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ucalgary_2024_chantal_rytz.pdf
Size:
7.4 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations